IMPRiND

Inhibiting misfolded protein propagation in neurodegenerative diseases
Inhibiting misfolded protein propagation in neurodegenerative diseases

FACTS & FIGURES

Start Date
End Date
Grant agreement number
116060

Contributions
IMI Funding
4 684 998
EFPIA in kind
6 365 900
Other
312 500
Total Cost11 363 398

Summary

Alzheimer’s and Parkinson’s diseases are neurodegenerative disorders that affect 45 million and 10 million people worldwide respectively. There is currently no cure for these diseases, which place an immense burden on carers, many of whom are family members. Both diseases are characterised by the progressive loss of brain cells. Recent evidence suggests that this loss may be due to the release and uptake by brain cells of specific aggregated proteins (misfolded proteins which clump together leading to a progressive spreading of the degeneration). If these processes could be blocked, disease progression could be halted. However, the forces driving these processes are currently poorly understood. Working to change that is the IMPRiND project, which aims to understand how these aggregated proteins are handled once inside brain cells and how they are moved from cell to cell. To do this, the project team will work collaboratively to develop standardised tools and tests to establish disease-relevant mechanisms that could be targeted by drugs in the future.

Participants Show participants on map

EFPIA companies
  • AbbVie Ltd, Maidenhead, United Kingdom
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • H. Lundbeck A/S, Valby, Denmark
  • Institut De Recherches Servier S.A.S, Suresnes, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Novartis Pharma AG, Basel, Switzerland
Universities, research organisations, public bodies, non-profit groups
  • Aarhus Universitet, Aarhus C, Denmark
  • Biomedical Research Foundation, Academy of Athens, Athens, Greece
  • Centre National De La Recherche Scientifique, Paris, France
  • Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V., Bonn, Germany
  • The Medical Research Council, Swindon, United Kingdom
  • Universitaetsmedizin Goettingen, Georg-August-Universitaet, - Stiftung Oeffentlichen Rechts –, Goettingen, Germany
  • University of Cambridge, Cambridge, United Kingdom
  • University of Dundee, Dundee, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Université de Bordeaux, Bordeaux, France
  • Vib, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • SCIPROM Sàrl, St-Sulpice, Switzerland

CONTACT

Project leader
Kenneth Thirstrup
H. Lundbeck A/S
Project coordinator
George Tofaris
The Chancellor, Masters and Scholars of the University of Oxford
george.tofaris[at]ndcn.ox.ac.uk
Project office and general enquires
Dr. Kirsten Leufgen
SCIPROM
+41 216940412